170 related articles for article (PubMed ID: 30691192)
1. Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD.
Fadeev R; Chekanov A; Solovieva M; Bezborodova O; Nemtsova E; Dolgikh N; Fadeeva I; Senotov A; Kobyakova M; Evstratova Y; Yakubovskaya R; Akatov V
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691192
[TBL] [Abstract][Full Text] [Related]
2. [Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
Fadeev RS; Chekanov AV; Dolgikh NV; Akatov VS
Biofizika; 2012; 57(4):655-61. PubMed ID: 23035532
[TBL] [Abstract][Full Text] [Related]
3. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
4. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
[TBL] [Abstract][Full Text] [Related]
5. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
6. [Increase in resistance of A431 cancer cells to TRAIL-induced apoptosis in confluent cultures].
Fadeev RS; Chekanov AV; Dolgikh NV; Akatov VS
Biofizika; 2012; 57(4):649-54. PubMed ID: 23035531
[TBL] [Abstract][Full Text] [Related]
7. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
8. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
Pieczykolan JS; Kubiński K; Masłyk M; Pawlak SD; Pieczykolan A; Rózga PK; Szymanik M; Gałązka M; Teska-Kamińska M; Żerek B; Bukato K; Poleszak K; Jaworski A; Strożek W; Świder R; Zieliński R
Invest New Drugs; 2014 Dec; 32(6):1155-66. PubMed ID: 25182378
[TBL] [Abstract][Full Text] [Related]
9. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
10. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
[TBL] [Abstract][Full Text] [Related]
12. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293545
[TBL] [Abstract][Full Text] [Related]
13. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
14. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
15. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
16. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro.
Goto M; Owaki K; Hirata A; Yanai T; Sakai H
Vet Comp Oncol; 2019 Sep; 17(3):285-297. PubMed ID: 30767429
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
19. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.
Polanski R; Vincent J; Polanska UM; Petreus T; Tang EK
Cell Death Dis; 2015 Oct; 6(10):e1893. PubMed ID: 26426685
[TBL] [Abstract][Full Text] [Related]
20. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
